Literature DB >> 7925730

Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies.

G W Comstock1.   

Abstract

When used to evaluate vaccination effectiveness, case-control studies are useful surrogates for controlled trials of vaccination programs. Their advantages over controlled trials are that 1) they involve relatively few participants, 2) the necessary information can be obtained within a short time, and 3) their results are based on actual field conditions. Their major and inescapable problem is producing convincing evidence that the vaccinated and unvaccinated populations are sufficiently alike in all relevant characteristics other than vaccination to allow a reasonable conclusion that vaccination effectiveness approximates vaccine efficacy. Even under uncontrolled circumstances, case-control studies should provide useful means of surveillance, indicating when some component of the vaccination program needs to be checked. Relative vaccine efficacy can be determined by case-control studies whenever the vaccine being used is the only factor in the vaccination program that has been changed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925730     DOI: 10.1093/oxfordjournals.epirev.a036147

Source DB:  PubMed          Journal:  Epidemiol Rev        ISSN: 0193-936X            Impact factor:   6.222


  12 in total

Review 1.  Appending epidemiological studies to conventional case-control studies (hybride case-control studies).

Authors:  Andreas Stang; Karl-Heinz Jöckel
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 2.  Evaluating the impact of influenza vaccination. A North American perspective.

Authors:  D S Fedson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

3.  ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or = 65 years.

Authors:  S A Skull; R M Andrews; G B Byrnes; D A Campbell; T M Nolan; G V Brown; H A Kelly
Journal:  Epidemiol Infect       Date:  2007-04-20       Impact factor: 2.451

4.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

Authors:  M R Lagranderie; A M Balazuc; E Deriaud; C D Leclerc; M Gheorghiu
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

Review 5.  Pneumococcal vaccination for older adults: the first 20 years.

Authors:  D S Fedson
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

6.  A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Authors:  Carolyn M Shoen; Michelle S DeStefano; Cynthia C Hager; Kyi-Toe Tham; Miriam Braunstein; Alexandria D Allen; Hiriam O Gates; Michael H Cynamon; Douglas S Kernodle
Journal:  Vaccines (Basel)       Date:  2013-01-11

7.  The effect of vaccination coverage and climate on Japanese encephalitis in Sarawak, Malaysia.

Authors:  Daniel E Impoinvil; Mong How Ooi; Peter J Diggle; Cyril Caminade; Mary Jane Cardosa; Andrew P Morse; Matthew Baylis; Tom Solomon
Journal:  PLoS Negl Trop Dis       Date:  2013-08-08

8.  Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Authors:  Jacques Montplaisir; Dominique Petit; Marie-Josée Quinn; Manale Ouakki; Geneviève Deceuninck; Alex Desautels; Emmanuel Mignot; Philippe De Wals
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

9.  Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG.

Authors:  Shanmugalakshmi Sadagopal; Miriam Braunstein; Cynthia C Hager; Jie Wei; Alexandria K Daniel; Markian R Bochan; Ian Crozier; Nathaniel E Smith; Hiriam O Gates; Louise Barnett; Luc Van Kaer; James O Price; Timothy S Blackwell; Spyros A Kalams; Douglas S Kernodle
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

10.  Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi.

Authors:  Naor Bar-Zeev; Lester Kapanda; Carina King; James Beard; Tambosi Phiri; Hazzie Mvula; Amelia C Crampin; Charles Mwansambo; Anthony Costello; Umesh Parashar; Jacqueline E Tate; Jennifer R Verani; Cynthia G Whitney; Robert S Heyderman; Nigel A Cunliffe; Neil French
Journal:  Vaccine       Date:  2015-04-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.